Batch Enrollment for AI-Guided Intervention to Lower Neurologic Events in Unrecognized AF
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04208971|
Recruitment Status : Enrolling by invitation
First Posted : December 23, 2019
Last Update Posted : November 12, 2020
|Condition or disease||Intervention/treatment|
|Atrial Fibrillation||Other: AI-enabled ECG-based Screening Tool for AF|
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Batch Enrollment for an Artificial Intelligence-Guided Intervention to Lower Neurologic Events in Patients With Unrecognized Atrial Fibrillation (BEAGLE)|
|Actual Study Start Date :||November 2, 2020|
|Estimated Primary Completion Date :||October 2021|
|Estimated Study Completion Date :||October 2022|
Adult patients who have not been previously diagnosed with AF, are eligible for anticoagulation and have AI-predicted risks based on a normal sinus rhythm ECG.
Other: AI-enabled ECG-based Screening Tool for AF
A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool to improve atrial fibrillation diagnosis and stroke prevention.
- Diagnosis of Atrial Fibrillation as Detected by Patch Application [ Time Frame: Three Months ]The data will be used to examine the performance of the algorithm in detecting unrecognized atrial fibrillation (e.g. positive predictive value, negative predictive value, sensitivity, specificity, and area under the curve [AUC]).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04208971
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Xiaoxi Yao, PhD, MPH||Mayo Clinic|
|Principal Investigator:||Peter Noseworthy, MD||Mayo Clinic|